NIH Considering Longer Paxlovid Course to Fight Reinfections

Published on May 18, 2022

The U.S. National Institutes of Health is discussing the possibility of studying whether a longer treatment with Pfizer’s antiviral drug Paxlovid can be more effective against reinfections. Dr. Anthony Fauci, a renowned infectious diseases expert, announced that talks are underway with Pfizer to explore this potential. It’s like having a vaccine VIP pass to dodge the virus all over again! Just as a VIP pass grants you access to exclusive areas at a concert or event, a longer course of Paxlovid might provide added protection against reinfection by SARS-CoV-2. This research can help us better understand the optimal duration of antiviral treatment and potentially enhance our fight against COVID-19. If we know that a longer course of treatment can significantly reduce reinfections, it could become an important strategy in managing the pandemic moving forward. Stay tuned for more information as these discussions progress!

The U.S. National Institutes of Health is in talks with Pfizer Inc about studying whether a longer course of the drugmaker’s COVID-19 antiviral treatment Paxlovid is needed to prevent reinfections, top U.S. infectious diseases expert Dr. Anthony Fauci said on…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>